Non-small Cell Lung Cancer Clinical Trials

851 recruitingLast updated: June 6, 2026

There are 851 actively recruiting non-small cell lung cancer clinical trials across 73 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, New York, New York, United States, Guangzhou, Guangdong, China. Updated daily from ClinicalTrials.gov.


Non-small Cell Lung Cancer Trials at a Glance

851 actively recruiting trials for non-small cell lung cancer are listed on ClinicalTrialsFinder across 6 cities in 73 countries. The largest study group is Phase 2 with 374 trials, with the heaviest enrollment activity in Houston, New York, and Guangzhou. Lead sponsors running non-small cell lung cancer studies include Hunan Province Tumor Hospital, AstraZeneca, and Sun Yat-sen University.

Browse non-small cell lung cancer trials by phase

Treatments under study

About Non-small Cell Lung Cancer Clinical Trials

Looking for clinical trials for Non-small Cell Lung Cancer? There are currently 578 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-small Cell Lung Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-small Cell Lung Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 851 trials

Recruiting
Phase 2Phase 3

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled311 locationsNCT07063745
Recruiting
Phase 1Phase 2

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

MelanomaNon-small Cell Lung CancerThyroid Cancer+10 more
Pfizer124 enrolled83 locationsNCT05538130
Recruiting

Standardization of a Platform of Preclinical Models Derived From NSCLC Patients

Non-small Cell Lung Cancer
Regina Elena Cancer Institute5 enrolled1 locationNCT07629375
Recruiting
Phase 2

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Squamous Cell CarcinomaAdvanced Non-Small Cell Lung CancerAdvanced NSCLC+2 more
National Cancer Institute (NCI)85 enrolled1 locationNCT02133196
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

MelanomaNon-small Cell Lung CancerThyroid Cancer+2 more
Pfizer267 enrolled40 locationsNCT05355701
Recruiting

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Non-small Cell Lung CancerMultiple MyelomaLymphoma, Non-Hodgkin+2 more
National Cancer Institute (NCI)500 enrolled1 locationNCT02682667
Recruiting
Phase 2Phase 3

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Non-squamous Non-small Cell Lung Cancer
AbbVie854 enrolled52 locationsNCT07005102
Recruiting
Phase 3

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled383 locationsNCT05920356
Recruiting
Phase 3

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Lung CancerNon-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+3 more
Pfizer1,410 enrolled346 locationsNCT07222566
Recruiting
Phase 2

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer
AbbVie150 enrolled72 locationsNCT06568939
Recruiting
Phase 1Phase 2

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Non-small Cell Lung CancerCarcinoma, Non-Small Cell LungAdvanced/Metastatic Non-Small Cell Lung Cancer
Pfizer162 enrolled45 locationsNCT07227298
Recruiting
Phase 1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Locally Advanced Hepatocellular CarcinomaLocally Advanced MelanomaMetastatic Hepatocellular Carcinoma+7 more
National Cancer Institute (NCI)30 enrolled1 locationNCT06066138
Recruiting
Phase 2

Boosting Osimertinib Blood Brain Barrier Penetration

Non-small Cell Lung Cancer
Maastricht University Medical Center7 enrolled2 locationsNCT07485452
Recruiting
Phase 3

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb850 enrolled255 locationsNCT07361497
Recruiting
Phase 1

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Non-small Cell Lung Cancer
University of Rochester60 enrolled2 locationsNCT04297605
Recruiting
Phase 1

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.604 enrolled17 locationsNCT06040541
Recruiting

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

Neoadjuvant TherapyNon-small Cell Lung CancerImmunotherapy+1 more
Peking University People's Hospital80 enrolled1 locationNCT07359040
Recruiting
Phase 2

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Non-small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-Small Cell Lung Cancer (Stage III)+5 more
Genelux Corporation142 enrolled15 locationsNCT06463665
Recruiting
Phase 1Phase 2

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Cervical CancerUrothelial CarcinomaMelanoma+8 more
Bristol-Myers Squibb1,109 enrolled47 locationsNCT04895709